wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q36098713-FD309E00-00CC-464B-8F10-9E5648ECF603
Q36098713-FD309E00-00CC-464B-8F10-9E5648ECF603
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36098713-FD309E00-00CC-464B-8F10-9E5648ECF603
Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
P2860
Q36098713-FD309E00-00CC-464B-8F10-9E5648ECF603
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36098713-FD309E00-00CC-464B-8F10-9E5648ECF603
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
9ae2fe3fc125a1dad0b428ef6dc2382b892e26e0
P2860
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.